Brinley F. Furey - Concepedia

Author

Brinley F. Furey

Vertex Pharmaceuticals (United States)

Also Known As

B. Furey, Brady Furey, Brinley F Furey, Brinley F. Furey, Brinley Furey, Furey, Brinley

Publications

819

Citations

H-Index

Concepts

All Affiliations

Vertex Pharmaceuticals (United States)Harvard University University of Maryland, Baltimore

About

Brinley F. Furey is an author at Vertex Pharmaceuticals (United States) specializing in medicine, cell biology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	321
2	Health Sciences	3	3	131
3	Cell Biology	3	3	131
4	Natural Sciences	1	1	40
5	Biochemistry	1	1	40

Brinley F. Furey

Publications

763

Citations

H-Index

Page 1

	Year	Citations
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib) Ursula A. Germann, Brinley F. Furey, William Markland, Molecular Cancer Therapeutics	2017	225
Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970 Amy B. Hall, Dave Newsome, Yuxin Wang, Oncotarget	2014	189
Neonatal sex hormones have `organizational' effects on the hypothalamic-pituitary-adrenal axis of male rats Cheryl M. McCormick, Brinley F. Furey, Meredith Child, Developmental Brain Research Endocrine MechanismBehavioral NeuroscienceMedicinePhysiologyNeuroendocrine Mechanism	1998	150
Deletion of the MAD2L1 spindle assembly checkpoint gene is tolerated in mouse models of acute T-cell lymphoma and hepatocellular carcinoma Floris Foijer, Lee A. Albacker, Björn Bakker, eLife CytogeneticsGeneticsMad2l1 SpindleCancer BiologyEpigenetics	2017	65
Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engine Raymond J. Winquist, Diane M. Boucher, Mark Wood, Biochemical Pharmacology Embryonic Stem CellInduced Pluripotent Stem CellMedicineLocomotive EngineStem Cell Mobilization	2009	45
Janus Kinase 2 Inhibitors. Synthesis and Characterization of a Novel Polycyclic Azaindole Tiansheng Wang, John P. Duffy, Jian Wang, Journal of Medicinal Chemistry Molecular PharmacologyMedicinal ChemistryDerivative (Chemistry)BiochemistryMedicine	2009	40
Abstract 4693: The selective ERK inhibitor BVD-523 is active in models of MAPK pathway-dependent cancers, including those with intrinsic and acquired drug resistance Ursula A. Germann, Brinley F. Furey, Jeff Roix, Cancer Research Chemoprevention StrategyCancer BiologyTumor BiologyDrug ResistanceOncology	2015	21
Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease Leslie Dakin, A H Fortier, Evanthia Nanou, Nature Communications	2025	16
Discovery and Optimization of Pyrazole Amides as Inhibitors of ELOVL1 Jon H. Come, Timothy J. Senter, Michael P. Clark, Journal of Medicinal Chemistry	2021	12

Page 1